Status:
COMPLETED
The Detection of EGFR Mutations in Liquid Based Cytology Samples
Lead Sponsor:
Royal Cornwall Hospitals Trust
Collaborating Sponsors:
Biocartis NV
Conditions:
Adenocarcinoma of Lung
Eligibility:
All Genders
18-100 years
Brief Summary
This study will investigate whether liquid based cytology specimens are a feasible alternative to formalin-fixed paraffin embedded histology samples for detection of epidermal growth factor receptor (...
Detailed Description
The presence of activating epidermal growth factor receptor (EGFR) mutations identifies patients with lung adenocarcinoma in which EGFR tyrosine kinase inhibitors (TKI) can be a potential first-line t...
Eligibility Criteria
Inclusion
- Diagnosis of lung adenocarcinoma by the cytology laboratory at Royal Cornwall Hospital Trust using the current, validated method on formalin-fixed paraffin embedded samples within the time period of the study. This will include both patients with wild type lung adenocarcinoma and also patients with lung adenocarcinoma with EGFR mutations.
Exclusion
- Samples received by the cytology laboratory following the sampling procedures that are not diagnosed as lung adenocarcinoma during the time period of the study.
Key Trial Info
Start Date :
May 7 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 24 2020
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT04086680
Start Date
May 7 2019
End Date
February 24 2020
Last Update
June 22 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cytopathology Laboratory Royal Cornwall Hospital
Truro, Cornwall, United Kingdom, TR1 3LQ